{
    "clinical_study": {
        "@rank": "60301", 
        "arm_group": {
            "arm_group_label": "SGN-CD19A", 
            "arm_group_type": "Experimental", 
            "description": "SGN-CD19A (IV) once every 21 days; dose range 0.5-6 mg/kg"
        }, 
        "brief_summary": {
            "textblock": "This is a phase 1, open-label, dose-escalation, multicenter study to evaluate the safety and\n      tolerability of SGN-CD19A in patients with relapsed or refractory B-lineage non-Hodgkin\n      lymphoma (B-NHL)"
        }, 
        "brief_title": "A Safety Study of SGN-CD19A for B-Cell Lymphoma", 
        "completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Burkitt Lymphoma", 
            "Lymphoma, Follicular", 
            "Lymphoma, Large B-Cell, Diffuse", 
            "Lymphoma, Mantle-Cell", 
            "Precursor B-cell Lymphoblastic Leukemia-Lymphoma"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Burkitt Lymphoma", 
                "Leukemia", 
                "Leukemia, Lymphoid", 
                "Precursor Cell Lymphoblastic Leukemia-Lymphoma", 
                "Precursor B-Cell Lymphoblastic Leukemia-Lymphoma", 
                "Lymphoma", 
                "Lymphoma, Follicular", 
                "Lymphoma, B-Cell", 
                "Lymphoma, Large B-Cell, Diffuse", 
                "Lymphoma, Mantle-Cell"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Pathologically confirmed diagnosis of mantle cell lymphoma, follicular lymphoma Grade\n             3, diffuse large B-cell lymphoma (DLBCL), including transformed follicular histology,\n             Burkitt lymphoma, or B-lineage lymphoblastic lymphoma\n\n          -  Relapsed, refractory, or progressive disease following at least 1 prior systemic\n             therapy.  Patients with DLBCL or follicular lymphoma Grade 3 must have also received\n             intensive salvage therapy.\n\n          -  Eastern Cooperative Oncology Group status of 0 or 1\n\n          -  Measurable disease\n\n        Exclusion Criteria:\n\n        - Allogeneic stem cell transplant (SCT)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "12 Years"
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 5, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01786135", 
            "org_study_id": "SGN19A-002"
        }, 
        "intervention": {
            "arm_group_label": "SGN-CD19A", 
            "description": "SGN-CD19A (IV) once every 21 days; dose range:  0.5-6 mg/kg", 
            "intervention_name": "SGN-CD19A", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Antibodies, Monoclonal", 
            "Antibody-Drug Conjugate", 
            "Antigens, CD19", 
            "B-Lineage Lymphoblastic Lymphoma", 
            "Burkitt Lymphoma", 
            "Diffuse Large B-Cell Lymphoma", 
            "Mantle Cell Lymphoma", 
            "B-Cell Lymphoma", 
            "Drug Therapy", 
            "Monomethylauristatin F", 
            "Follicular Lymphoma Grade 3"
        ], 
        "lastchanged_date": "May 30, 2014", 
        "location": [
            {
                "contact": {
                    "email": "sbiggers@uab.edu", 
                    "last_name": "Stephanie Biggers", 
                    "phone": "205-975-2944"
                }, 
                "facility": {
                    "address": {
                        "city": "Birmingham", 
                        "country": "United States", 
                        "state": "Alabama", 
                        "zip": "35294-3300"
                    }, 
                    "name": "University of Alabama at Birmingham"
                }, 
                "investigator": {
                    "last_name": "Andres Forero-Torres, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "gauravv@stanford.edu", 
                    "last_name": "Gaurav Varma", 
                    "phone": "650-723-0437"
                }, 
                "facility": {
                    "address": {
                        "city": "Stanford", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94305-5821"
                    }, 
                    "name": "Stanford Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Ranjana Advani, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "megan.borase@moffitt.org", 
                    "last_name": "Megan Borase", 
                    "phone": "813-745-2591"
                }, 
                "facility": {
                    "address": {
                        "city": "Tampa", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33612"
                    }, 
                    "name": "H. Lee Moffitt Cancer Center & Research Institute"
                }, 
                "investigator": {
                    "last_name": "Bijal Shah, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "jacoba@mskcc.org", 
                    "last_name": "Alexandra Jacob", 
                    "phone": "646-449-1304"
                }, 
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10021"
                    }, 
                    "name": "Memorial Sloan Kettering Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Craig Moskowitz, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "thutto@mdanderson.org", 
                    "last_name": "Toni Hutto", 
                    "phone": "713-792-1871"
                }, 
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77030-4000"
                    }, 
                    "name": "MD Anderson Cancer Center /The University of Texas"
                }, 
                "investigator": {
                    "last_name": "Michelle Fanale, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 1, Open-Label, Dose-Escalation Study of SGN-CD19A in Patients With Relapsed or Refractory B-Lineage Non-Hodgkin Lymphoma", 
        "overall_contact": {
            "email": "clinicaltrials@seagen.com", 
            "last_name": "Terri Lowe", 
            "phone": "866-333-7436"
        }, 
        "overall_official": {
            "affiliation": "Seattle Genetics, Inc.", 
            "last_name": "Ana Kostic, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Incidence of adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "Through 1 month post last dose"
            }, 
            {
                "measure": "Incidence of laboratory abnormalities", 
                "safety_issue": "Yes", 
                "time_frame": "Through 1 month post last dose"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01786135"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Objective response according to revised response criteria for malignant lymphoma (Cheson 2007)", 
                "safety_issue": "No", 
                "time_frame": "Through 1 month post last dose"
            }, 
            {
                "measure": "Duration of response", 
                "safety_issue": "No", 
                "time_frame": "Until disease progression or start of new anticancer treatment, an expected average of 6 months"
            }, 
            {
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "Until death or study closure, an expected average of 1 year"
            }, 
            {
                "measure": "Blood concentration of SGN-CD19A and metabolites", 
                "safety_issue": "No", 
                "time_frame": "Cycles 1, 2, and 4:  predose, 30 minutes, and  2, 4, 8, 24, 72, 120, 168, and 336 hours post dose start; All other cycles:  predose, 30 minutes, and 168 and 336 hours post dose start, and 1 month post last dose"
            }, 
            {
                "measure": "Incidence of antitherapeutic antibodies", 
                "safety_issue": "Yes", 
                "time_frame": "Predose in most cycles and 1 month post last dose"
            }
        ], 
        "source": "Seattle Genetics, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Seattle Genetics, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}